ArticleThe Journal of antibiotics2026
Artificial intelligence-based phenotypic screening using Aspergillus oryzae identified a novel antifungal RK-1205-I.
Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
When treated with various compounds, fungi exhibit characteristic morphological changes depending on their mode of action. Previously, we constructed morphology-based databases of the rice blast fungus Pyricularia oryzae and human pathogenic fungus Candida albicans and used them for antifungal screening. As these databases are manually created by human experts, objectivity and throughput may be a concern. To overcome these limitations, we developed a new artificial intelligence (AI)-based automated classification system for morphological changes in the filamentous fungus Aspergillus oryzae. Using this system, we screened a library of 7602 microbial broths and found that the culture broth of Streptomyces sp. RK21-A1205 exhibited potent antifungal activity and induced unique morphological changes distinct from those induced by conventional antifungal agents. Antifungal-activity-guided purification yielded the active metabolite RK-1205-I (1), whose chemical structure was identified as a new fostriecin derivative. 1 showed strong growth inhibitory activity against A. oryzae and other fungi, including A. fumigatus and C. auris, with IC
Indexed as
Identifiers
42321440What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.